Clinical Trial Update: A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating adding rituximab (MabThera) to standard treatment in idiopathic thrombocytopenic purpura (ITP) has completed with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• MabThera (Rituximab) (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Idiopathic Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED | Results posted: 2014-10-22